Age Related Macular Degeneration - Pipeline Review, H2 2016

 

Rating

4.9 Star Rating for report Age Related Macular Degeneration - Pipeline Review, H2 2016
4.9 / 5 stars rating
Pages: 563
Price: $2000.00

Some of our Clients

Some Research and Expert Clients

Abstract

 
Age related macular degeneration is the most common reason for vision loss in people aged above 50. It results in depreciation of the macula that may lead to distorted or blurry central vision. The predisposing factors involved are age, smoking, sunlight, heredity etc. Symptoms include development of blind spot and hazy vision. The condition may be treated by photodynamic therapy, radiation therapy and medication such as anti-angiogenic drugs.  

Description

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Age Related Macular Degeneration - Pipeline Review, H2 2016, provides an overview of the Age Related Macular Degeneration (Ophthalmology) pipeline landscape.

Age related macular degeneration is the most common reason for vision loss in people aged above 50. It results in depreciation of the macula that may lead to distorted or blurry central vision. The predisposing factors involved are age, smoking, sunlight, heredity etc. Symptoms include development of blind spot and hazy vision. The condition may be treated by photodynamic therapy, radiation therapy and medication such as anti-angiogenic drugs.
 

Similar Reports

Other reports that may be of interest...

Report... 05IB-GMDHC8841IDBFemale Sexual Dysfunction - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8840IDBRhino-Conjunctivitis - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8831IDBVasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Review,...Dec 2016
Report... 05IB-GMDHC8828IDBRetinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8803IDBCervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2...Dec 2016
Report... 05IB-GMDHC8802IDBGraves' Ophthalmopathy - Pipeline Review, H2 2016Dec 2016
Report... 05IC-GDME0301EPDClinical IT (Information Technology) Systems - Medical Devices P...Dec 2016
Report... 01L7-HIT2237Clinical Decision Support Systems Market - Forecasts to 2021Dec 2016
Report... 01L7-HIT3542Telehealth Market - Forecast to 2021 Dec 2016

Report Source Information

Supplied by: Research and Experts 
Date Published: 2016-12-14 

Report: Age Related Macular Degeneration - Pipeline Review, H2 2016

 

Contents

Table of Contents
Table of Contents 2
Introduction 7
Age Related Macular Degeneration Overview 8
Therapeutics Development 9
Age Related Macular Degeneration - Therapeutics under Development by Companies 11
Age Related Macular Degeneration - Therapeutics under Investigation by Universities/Institutes 21
Age Related Macular Degeneration - Pipeline Products Glance 23
Age Related Macular Degeneration - Products under Development by Companies 26
Age Related Macular Degeneration - Products under Investigation by Universities/Institutes 39
Age Related Macular Degeneration - Companies Involved in Therapeutics Development 40
Age Related Macular Degeneration - Therapeutics Assessment 160
Drug Profiles 176
Age Related Macular Degeneration - Dormant Projects 513
Age Related Macular Degeneration - Discontinued Products 528
Age Related Macular Degeneration - Product Development Milestones 530
Appendix 539
 

List of Tables

List of Tables
Number of Products under Development for Age Related Macular Degeneration, H2 2016 32
Number of Products under Development for Age Related Macular Degeneration - Comparative Analysis, H2 2016 33
Number of Products under Development by Companies, H2 2016 34
Number of Products under Development by Companies, H2 2016 (Contd..1) 35
Number of Products under Development by Companies, H2 2016 (Contd..2) 36
Number of Products under Development by Companies, H2 2016 (Contd..3) 37
Number of Products under Development by Companies, H2 2016 (Contd..4) 38
Number of Products under Development by Companies, H2 2016 (Contd..5) 39
Number of Products under Development by Companies, H2 2016 (Contd..6) 40
Number of Products under Development by Companies, H2 2016 (Contd..7) 41
Number of Products under Development by Companies, H2 2016 (Contd..8) 42
Number of Products under Development by Companies, H2 2016 (Contd..9) 43
Number of Products under Investigation by Universities/Institutes, H2 2016 45
Comparative Analysis by Late Stage Development, H2 2016 46
Comparative Analysis by Clinical Stage Development, H2 2016 47
Comparative Analysis by Early Stage Development, H2 2016 48
Products under Development by Companies, H2 2016 49
Products under Development by Companies, H2 2016 (Contd..1) 50
Products under Development by Companies, H2 2016 (Contd..2) 51
Products under Development by Companies, H2 2016 (Contd..3) 52
Products under Development by Companies, H2 2016 (Contd..4) 53
Products under Development by Companies, H2 2016 (Contd..5) 54
Products under Development by Companies, H2 2016 (Contd..6) 55
Products under Development by Companies, H2 2016 (Contd..7) 56
Products under Development by Companies, H2 2016 (Contd..8) 57
Products under Development by Companies, H2 2016 (Contd..9) 58
Products under Development by Companies, H2 2016 (Contd..10) 59
Products under Development by Companies, H2 2016 (Contd..11) 60
Products under Development by Companies, H2 2016 (Contd..12) 61
Products under Investigation by Universities/Institutes, H2 2016 62
Age Related Macular Degeneration - Pipeline by 3SBio Inc, H2 2016 63
Age Related Macular Degeneration - Pipeline by AC Immune SA, H2 2016 64
Age Related Macular Degeneration - Pipeline by Achillion Pharmaceuticals Inc, H2 2016 65
Age Related Macular Degeneration - Pipeline by Aciont Inc, H2 2016 66
Age Related Macular Degeneration - Pipeline by Acucela Inc, H2 2016 67
Age Related Macular Degeneration - Pipeline by AdAlta Ltd, H2 2016 68
Age Related Macular Degeneration - Pipeline by Adverum Biotechnologies Inc, H2 2016 69
Age Related Macular Degeneration - Pipeline by Aerie Pharmaceuticals Inc, H2 2016 70
Age Related Macular Degeneration - Pipeline by Aerpio Therapeutics Inc, H2 2016 71
Age Related Macular Degeneration - Pipeline by Alimera Sciences Inc, H2 2016 72
Age Related Macular Degeneration - Pipeline by Alkeus Pharmaceuticals Inc, H2 2016 73
Age Related Macular Degeneration - Pipeline by Allergan Plc, H2 2016 74
Age Related Macular Degeneration - Pipeline by Allinky Biopharma, H2 2016 75
Age Related Macular Degeneration - Pipeline by Alteogen Inc, H2 2016 76
Age Related Macular Degeneration - Pipeline by Amakem NV, H2 2016 77
Age Related Macular Degeneration - Pipeline by Amarna Therapeutics BV, H2 2016 78
Age Related Macular Degeneration - Pipeline by Ampio Pharmaceuticals Inc, H2 2016 79
Age Related Macular Degeneration - Pipeline by Amyndas Pharmaceuticals LLC, H2 2016 80
Age Related Macular Degeneration - Pipeline by ANP Technologies Inc, H2 2016 81
Age Related Macular Degeneration - Pipeline by Apellis Pharmaceuticals Inc, H2 2016 82
Age Related Macular Degeneration - Pipeline by Apexigen Inc, H2 2016 83
Age Related Macular Degeneration - Pipeline by Applied Genetic Technologies Corp, H2 2016 84
Age Related Macular Degeneration - Pipeline by Astellas Pharma Inc, H2 2016 85
Age Related Macular Degeneration - Pipeline by Benitec Biopharma Ltd, H2 2016 86
Age Related Macular Degeneration - Pipeline by Biokine Therapeutics Ltd, H2 2016 87
Age Related Macular Degeneration - Pipeline by BioMAS Ltd, H2 2016 88
Age Related Macular Degeneration - Pipeline by Biomics Biotechnologies Co Ltd, H2 2016 89
Age Related Macular Degeneration - Pipeline by Biophytis SAS, H2 2016 90
Age Related Macular Degeneration - Pipeline by BLR Bio LLC, H2 2016 91
Age Related Macular Degeneration - Pipeline by Boehringer Ingelheim GmbH, H2 2016 92
Age Related Macular Degeneration - Pipeline by Caladrius Biosciences Inc, H2 2016 93
Age Related Macular Degeneration - Pipeline by Catalyst Biosciences Inc, H2 2016 94
Age Related Macular Degeneration - Pipeline by Cell Cure Neurosciences Ltd, H2 2016 95
Age Related Macular Degeneration - Pipeline by Cell Medica Ltd, H2 2016 96
Age Related Macular Degeneration - Pipeline by Charlesson LLC, H2 2016 97
Age Related Macular Degeneration - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2016 98
Age Related Macular Degeneration - Pipeline by Cipla Ltd, H2 2016 99
Age Related Macular Degeneration - Pipeline by Clanotech AB, H2 2016 100
Age Related Macular Degeneration - Pipeline by Clearside BioMedical Inc, H2 2016 101
Age Related Macular Degeneration - Pipeline by Coherus BioSciences Inc, H2 2016 102
Age Related Macular Degeneration - Pipeline by Colby Pharmaceutical Company, H2 2016 103
Age Related Macular Degeneration - Pipeline by Crinetics Pharmaceuticals Inc, H2 2016 104
Age Related Macular Degeneration - Pipeline by Critical Pharmaceuticals Ltd, H2 2016 105
Age Related Macular Degeneration - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 106
Age Related Macular Degeneration - Pipeline by Diffusion Pharmaceuticals Inc, H2 2016 107
Age Related Macular Degeneration - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2016 108
Age Related Macular Degeneration - Pipeline by Eleven Biotherapeutics Inc., H2 2016 109
Age Related Macular Degeneration - Pipeline by Elsalys Biotech SAS, H2 2016 110
Age Related Macular Degeneration - Pipeline by Exonate Ltd, H2 2016 111
Age Related Macular Degeneration - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 112
Age Related Macular Degeneration - Pipeline by FirstString Research Inc, H2 2016 113
Age Related Macular Degeneration - Pipeline by Foamix Pharmaceuticals Ltd, H2 2016 114
Age Related Macular Degeneration - Pipeline by Formycon AG, H2 2016 115
Age Related Macular Degeneration - Pipeline by Gene Techno Science Co Ltd, H2 2016 116
Age Related Macular Degeneration - Pipeline by Genentech Inc, H2 2016 117
Age Related Macular Degeneration - Pipeline by GenSight Biologics SA, H2 2016 118
Age Related Macular Degeneration - Pipeline by GlaxoSmithKline Plc, H2 2016 119
Age Related Macular Degeneration - Pipeline by Graybug Vision Inc, H2 2016 120
Age Related Macular Degeneration - Pipeline by Grupo Ferrer Internacional SA, H2 2016 121
Age Related Macular Degeneration - Pipeline by HanAll Biopharma Co Ltd, H2 2016 122
Age Related Macular Degeneration - Pipeline by Huabo Biopharm Co Ltd, H2 2016 123
Age Related Macular Degeneration - Pipeline by iCo Therapeutics Inc., H2 2016 124
Age Related Macular Degeneration - Pipeline by Icon Bioscience Inc, H2 2016 125
Age Related Macular Degeneration - Pipeline by Iconic Therapeutics Inc, H2 2016 126
Age Related Macular Degeneration - Pipeline by Inception Sciences Inc, H2 2016 127
Age Related Macular Degeneration - Pipeline by Innovent Biologics Inc, H2 2016 128
Age Related Macular Degeneration - Pipeline by Intellect Neurosciences Inc, H2 2016 129
Age Related Macular Degeneration - Pipeline by International Stem Cell Corp, H2 2016 130
Age Related Macular Degeneration - Pipeline by Ionis Pharmaceuticals Inc, H2 2016 131
Age Related Macular Degeneration - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016 132
Age Related Macular Degeneration - Pipeline by Johnson & Johnson, H2 2016 133
Age Related Macular Degeneration - Pipeline by Kala Pharmaceuticals Inc, H2 2016 134
Age Related Macular Degeneration - Pipeline by Kodiak Sciences Inc, H2 2016 135
Age Related Macular Degeneration - Pipeline by Lead Discovery Center GmbH, H2 2016 136
Age Related Macular Degeneration - Pipeline by LeadArtis SL, H2 2016 137
Age Related Macular Degeneration - Pipeline by M's Science Corp, H2 2016 138
Age Related Macular Degeneration - Pipeline by Mabion SA, H2 2016 139
Age Related Macular Degeneration - Pipeline by MacuCLEAR Inc, H2 2016 140
Age Related Macular Degeneration - Pipeline by MeiraGTx Ltd, H2 2016 141
Age Related Macular Degeneration - Pipeline by Mitotech SA, H2 2016 142
Age Related Macular Degeneration - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2016 143
Age Related Macular Degeneration - Pipeline by Mor Research Application Ltd, H2 2016 144
Age Related Macular Degeneration - Pipeline by Navigen Pharmaceuticals Inc, H2 2016 145
Age Related Macular Degeneration - Pipeline by Navya Biologicals Pvt Ltd, H2 2016 146
Age Related Macular Degeneration - Pipeline by Neovacs SA, H2 2016 147
Age Related Macular Degeneration - Pipeline by Neumedicines Inc, H2 2016 148
Age Related Macular Degeneration - Pipeline by Neuroptis Biotech, H2 2016 149
Age Related Macular Degeneration - Pipeline by Novartis AG, H2 2016 150
Age Related Macular Degeneration - Pipeline by NovelMed Therapeutics Inc, H2 2016 151
Age Related Macular Degeneration - Pipeline by Ocular Therapeutix Inc, H2 2016 152
Age Related Macular Degeneration - Pipeline by Ohr Pharmaceutical Inc, H2 2016 153
Age Related Macular Degeneration - Pipeline by Omeros Corp, H2 2016 154
Age Related Macular Degeneration - Pipeline by Ophthotech Corp, H2 2016 155
Age Related Macular Degeneration - Pipeline by Oxford BioMedica Plc, H2 2016 156
Age Related Macular Degeneration - Pipeline by PanOptica Inc, H2 2016 157
Age Related Macular Degeneration - Pipeline by Pfenex Inc, H2 2016 158
Age Related Macular Degeneration - Pipeline by Pfizer Inc, H2 2016 159
Age Related Macular Degeneration - Pipeline by Precision Ocular Ltd, H2 2016 160
Age Related Macular Degeneration - Pipeline by Promedior Inc, H2 2016 161
Age Related Macular Degeneration - Pipeline by pSivida Corp, H2 2016 162
Age Related Macular Degeneration - Pipeline by QLT Inc, H2 2016 163
Age Related Macular Degeneration - Pipeline by Ra Pharmaceuticals Inc, H2 2016 164
Age Related Macular Degeneration - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 165
Age Related Macular Degeneration - Pipeline by RegenxBio Inc, H2 2016 166
Age Related Macular Degeneration - Pipeline by Retrotope Inc, H2 2016 167
Age Related Macular Degeneration - Pipeline by Ribomic Inc, H2 2016 168
Age Related Macular Degeneration - Pipeline by RXi Pharmaceuticals Corp, H2 2016 169
Age Related Macular Degeneration - Pipeline by Samumed LLC, H2 2016 170
Age Related Macular Degeneration - Pipeline by SanBio Inc, H2 2016 171
Age Related Macular Degeneration - Pipeline by Santen Pharmaceutical Co Ltd, H2 2016 172
Age Related Macular Degeneration - Pipeline by SciFluor Life Sciences LLC, H2 2016 173
Age Related Macular Degeneration - Pipeline by Stealth BioTherapeutics Inc, H2 2016 174
Age Related Macular Degeneration - Pipeline by Sucampo Pharmaceuticals Inc, H2 2016 175
Age Related Macular Degeneration - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 176
Age Related Macular Degeneration - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2016 177
Age Related Macular Degeneration - Pipeline by TRACON Pharmaceuticals Inc, H2 2016 178
Age Related Macular Degeneration - Pipeline by TWi Pharmaceuticals Inc, H2 2016 179
Age Related Macular Degeneration - Pipeline by Tyrogenex Inc, H2 2016 180
Age Related Macular Degeneration - Pipeline by Wellstat Ophthalmics Corp, H2 2016 181
Age Related Macular Degeneration - Pipeline by Xbrane Biopharma AB, H2 2016 182
Assessment by Monotherapy Products, H2 2016 183
Assessment by Combination Products, H2 2016 184
Number of Products by Stage and Target, H2 2016 186
Number of Products by Stage and Mechanism of Action, H2 2016 191
Number of Products by Stage and Route of Administration, H2 2016 196
Number of Products by Stage and Molecule Type, H2 2016 198
Age Related Macular Degeneration - Dormant Projects, H2 2016 536
Age Related Macular Degeneration - Dormant Projects (Contd..1), H2 2016 537
Age Related Macular Degeneration - Dormant Projects (Contd..2), H2 2016 538
Age Related Macular Degeneration - Dormant Projects (Contd..3), H2 2016 539
Age Related Macular Degeneration - Dormant Projects (Contd..4), H2 2016 540
Age Related Macular Degeneration - Dormant Projects (Contd..5), H2 2016 541
Age Related Macular Degeneration - Dormant Projects (Contd..6), H2 2016 542
Age Related Macular Degeneration - Dormant Projects (Contd..7), H2 2016 543
Age Related Macular Degeneration - Dormant Projects (Contd..8), H2 2016 544
Age Related Macular Degeneration - Dormant Projects (Contd..9), H2 2016 545
Age Related Macular Degeneration - Dormant Projects (Contd..10), H2 2016 546
Age Related Macular Degeneration - Dormant Projects (Contd..11), H2 2016 547
Age Related Macular Degeneration - Dormant Projects (Contd..12), H2 2016 548
Age Related Macular Degeneration - Dormant Projects (Contd..13), H2 2016 549
Age Related Macular Degeneration - Dormant Projects (Contd..14), H2 2016 550
Age Related Macular Degeneration - Discontinued Products, H2 2016 551
Age Related Macular Degeneration - Discontinued Products (Contd..1), H2 2016 552
 

List of Figures

List of Figures
Number of Products under Development for Age Related Macular Degeneration, H2 2016 32
Number of Products under Development for Age Related Macular Degeneration - Comparative Analysis, H2 2016 33
Number of Products under Development by Companies, H2 2016 34
Number of Products under Investigation by Universities/Institutes, H2 2016 44
Comparative Analysis by Late Stage Development, H2 2016 46
Comparative Analysis by Clinical Stage Development, H2 2016 47
Comparative Analysis by Early Stage Products, H2 2016 48
Assessment by Monotherapy Products, H2 2016 183
Number of Products by Top 10 Targets, H2 2016 185
Number of Products by Stage and Top 10 Targets, H2 2016 185
Number of Products by Top 10 Mechanism of Actions, H2 2016 190
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 190
Number of Products by Top 10 Routes of Administration, H2 2016 195
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 195
Number of Products by Top 10 Molecule Types, H2 2016 197
Number of Products by Stage and Top 10 Molecule Types, H2 2016 197
 

Scope


- The pipeline guide provides a snapshot of the global therapeutic landscape of Age Related Macular Degeneration (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Age Related Macular Degeneration (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Age Related Macular Degeneration (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Age Related Macular Degeneration (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Age Related Macular Degeneration (Ophthalmology)

 

Highlights

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Age Related Macular Degeneration - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Age Related Macular Degeneration (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Age Related Macular Degeneration (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Age Related Macular Degeneration and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 8, 33, 11, 109 and 31 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 15 and 2 molecules, respectively.Age Related Macular Degeneration.

Age Related Macular Degeneration (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

 

Classification

Language Code: EN 
Region: Global 
Report Type: Market Report 
Industry: Life Sciences 
Sector: Healthcare 
Pages: 563 

Companies Featured

3SBio Inc AC Immune SA Achillion Pharmaceuticals Inc Aciont Inc Acucela Inc AdAlta Ltd Adverum Biotechnologies Inc Aerie Pharmaceuticals Inc Aerpio Therapeutics Inc Alimera Sciences Inc Alkeus Pharmaceuticals Inc Allergan Plc Allinky Biopharma Alteogen Inc Amakem NV Amarna Therapeutics BV Ampio Pharmaceuticals Inc Amyndas Pharmaceuticals LLC ANP Technologies Inc Apellis Pharmaceuticals Inc Apexigen Inc Applied Genetic Technologies Corp Astellas Pharma Inc Benitec Biopharma Ltd Biokine Therapeutics Ltd BioMAS Ltd Biomics Biotechnologies Co Ltd Biophytis SAS BLR Bio LLC Boehringer Ingelheim GmbH Caladrius Biosciences Inc Catalyst Biosciences Inc Cell Cure Neurosciences Ltd Cell Medica Ltd Charlesson LLC Chong Kun Dang Pharmaceutical Corp Cipla Ltd Clanotech AB Clearside BioMedical Inc Coherus BioSciences Inc Colby Pharmaceutical Company Crinetics Pharmaceuticals Inc Critical Pharmaceuticals Ltd Daiichi Sankyo Company Ltd Diffusion Pharmaceuticals Inc Dong-A Socio Holdings Co Ltd Eleven Biotherapeutics Inc. Elsalys Biotech SAS Exonate Ltd F. Hoffmann-La Roche Ltd FirstString Research Inc Foamix Pharmaceuticals Ltd Formycon AG Gene Techno Science Co Ltd Genentech Inc GenSight Biologics SA GlaxoSmithKline Plc Graybug Vision Inc Grupo Ferrer Internacional SA HanAll Biopharma Co Ltd Huabo Biopharm Co Ltd iCo Therapeutics Inc. Icon Bioscience Inc Iconic Therapeutics Inc Inception Sciences Inc Innovent Biologics Inc Intellect Neurosciences Inc International Stem Cell Corp Ionis Pharmaceuticals Inc Jeil Pharmaceutical Co Ltd Johnson & Johnson Kala Pharmaceuticals Inc Kodiak Sciences Inc Lead Discovery Center GmbH LeadArtis SL M's Science Corp Mabion SA MacuCLEAR Inc MeiraGTx Ltd Mitotech SA Mitsubishi Tanabe Pharma Corp Mor Research Application Ltd Navigen Pharmaceuticals Inc Navya Biologicals Pvt Ltd Neovacs SA Neumedicines Inc Neuroptis Biotech Novartis AG NovelMed Therapeutics Inc Ocular Therapeutix Inc Ohr Pharmaceutical Inc Omeros Corp Ophthotech Corp Oxford BioMedica Plc PanOptica Inc Pfenex Inc Pfizer Inc Precision Ocular Ltd Promedior Inc pSivida Corp QLT Inc Ra Pharmaceuticals Inc Regeneron Pharmaceuticals Inc RegenxBio Inc Retrotope Inc Ribomic Inc RXi Pharmaceuticals Corp Samumed LLC SanBio Inc Santen Pharmaceutical Co Ltd SciFluor Life Sciences LLC Stealth BioTherapeutics Inc Sucampo Pharmaceuticals Inc Sumitomo Dainippon Pharma Co Ltd Sun Pharma Advanced Research Company Ltd TRACON Pharmaceuticals Inc TWi Pharmaceuticals Inc Tyrogenex Inc Wellstat Ophthalmics Corp Xbrane Biopharma AB

 

Reasons to buy this report


- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Age Related Macular Degeneration (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Age Related Macular Degeneration (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 

Similar Reports

Other reports that may be of interest...

Report... 05IB-GMDHC8841IDBFemale Sexual Dysfunction - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8840IDBRhino-Conjunctivitis - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8831IDBVasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Review,...Dec 2016
Report... 05IB-GMDHC8828IDBRetinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8803IDBCervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2...Dec 2016
Report... 05IB-GMDHC8802IDBGraves' Ophthalmopathy - Pipeline Review, H2 2016Dec 2016
Report... 05IC-GDME0301EPDClinical IT (Information Technology) Systems - Medical Devices P...Dec 2016
Report... 01L7-HIT2237Clinical Decision Support Systems Market - Forecasts to 2021Dec 2016
Report... 01L7-HIT3542Telehealth Market - Forecast to 2021 Dec 2016

Age Related Macular Degeneration - Pipeline Review, H2 2016

Report 05IB-GMDHC8804IDB has a rating of 97 percent
Figure of merit assessment for report 05IB-GMDHC8804IDB

Relevance Rating

The Research and Experts relevance ranting consists of a set of figure of merit (FOM) values that are provided as an indication of the value of the report in the current economic environment.

These FOM values cannot take into account the reason for the clients interest in a report and therefore the client should view these FOM values only as a visual guide. The FOM scores are based on

market interest - how often the report is viewed or purchased,
elapsed time - time since the report was published,
report detail - amount of detail in the report (pages, figures, images, comments etc.) and
price - the price of the report.


Regional Information

Taxonomy

Branch ID: 1591

Taxonomy Location

The taxonomy on the left shows the ancestors of the Global node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Global

The global economy is the economy of all the world's countries. The total world population now stands at over 7 billion and the global unemployment rate is 9% with approximately half the world's population paid less than $2 a day. 

The global economy is picking up again after five years of uncertaintity and slow economic growth. The IMF is predicting global growth of 3.7% in 2014 rising to 3.9% in 2015. However, much uncertainity remains. Low inflation in developed economies means that these economies take longer to deal with debt burdens and are at increases risk of deflation. 

The second half of 2013 saw growth in the US and European economies (particularly UK, Germany and France).  

Growth in the US has been helped by cheaper energy from fracking , renewables and more oil and gas exploration. This cheaper energy is bring manufacturing jobs back to the US and helping to boost domestic demand. Recent winter weather conditions have hampered growth in the construction sector and have slowed demand in the construction equipment sector which saw exports drop by 25% in 2013. Growth should pick up in this sector with continued federal investment in infrastructure, new residential house builds and refurbishment and the energy boom.

In Europe growth is expected to be uneven with growth being slow in stressed economies such as Portugal and Greece but confidence picking up in UK, Ireland and even Spain showing some improvement.

Developing economies such as China and India will continue to have strong growth in 2014 and 2015. China has benefitted from increased investment with the Chinese govenment now focused on quality growth of 7.5% in 2014. India which is less reliant on exports expects growth of 5.4% in 2014 and 6.4% in 2015.

Much uncertainity still remains in the global economy with greater optimism needed to stabilise growth.

Links

World Bank

IMF (International Monetary Fund)

 

 

Zones

Regional zones

 

Country

Countries

 

Industry Sector Information

Taxonomy

Branch ID: 505

Taxonomy Location

The taxonomy on the left shows the ancestors of the Healthcare node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Healthcare

The healthcare industry is changing rapidly due to changes in legislation (US Affordable Healthcare Act),  advances in IT and more pressures on governments and healthcare providers due to rising costs. 

According to a recent report by the OECD healthcare spending has fallen in one third of OECD member states due to the credit crunch and members are facing up to the challenge of providing greater care with fewer resources. Spending on healthcare has increased in Japan, Israel and Korea while it has dropped dramatically in Greece and Ireland.

Useful Links

World Health Organisation 

American Healthcare Association

The British Healthcare Business Intelligence Association

OECD, Health Policies and Data

Healthcare

Life Sciences

The Life Sciences industry includes biotechnology, healthcare, pharmaceuticals, medical devices and diagnostics. The industry is dominated by US companies requiring considerable investment in research and development to stay competitive.  While US companies dominate this space, competition is emerging from smaller companies in Europe and Asia. 

Companies trying to stay competitive or enter new markets in life sciences consult our reports. For example, Plimsoll, in their recent review of global antibiotic manufacturers have reviewed 150 of the largest manufacturers including analysis of  ANTIBIOTICE SA, BAYER HEALTHCARE MANUFACTURING SRL and CIPLA LTD. 

Our reports are a requirement for companies looking for the best competitive intelligence in the life sciences sector providing information on market size, rankings, best trading partners and financial analysis. 

Useful Links

Analytical Life Sciences and Diagnostics Association

German Life Sciences Association

 

Life Sciences

Industry

Industries

 

 

Buy: Age Related Macular Degeneration - Pipeline Review, H2 2016

 

Item Code: 05IB-GMDHC8804IDB

 
Licence: Single User
Price: $2000.00
 
VAT: 0.0% 
Total: $2000.00 

Feedback

Return to Research and Experts

Page created and rendered - Cache updated [0.26433s]

--